Paying Peer Reviewers: What the 2026 Experiments Mean for Medical Authors

The academic peer review system runs on volunteer labor, and that labor is becoming harder to recruit. The rate at which researchers accept peer review invitations has declined sharply over the past several years. Editors at many medical journals now send four or five invitations before a single reviewer agrees to take a manuscript. When someone does accept, they may take six to eight weeks to return a report, or they may never respond at all. The system has not collapsed, but the signs of strain are measurable and worsening.

Into this situation, the journal Biology Open has offered the most concrete evidence to date that financial compensation changes reviewer behavior in ways that matter to authors. A preprint posted in June 2026 by the journal's editors, followed by a Nature analysis published July 1, 2026, laid out results from the expanded rollout of what the journal calls its Fast and Fair model. The numbers are striking enough that editors at other journals, including medical titles, are paying attention.

Medical authors care about this for practical reasons. Decision speed affects career timelines, grant renewals, thesis defenses, and priority claims. A system that takes eight weeks to return a first decision is not just slow; it shapes which journals researchers target, which manuscripts get submitted where, and how competitive a research group can be. If payment proves to scale beyond a single biology journal, it could shift norms across biomedical publishing within a few years.

Why the Reviewer Shortage Is Getting Worse

The peer review labor problem has multiple roots, and they compound each other. The number of manuscripts submitted to biomedical journals has grown steadily for two decades, accelerated by the expansion of institutional incentives for publication and the rise of multi-site research collaborations. The pool of qualified reviewers has not grown at the same pace. At the same time, the proportion of researchers willing to accept review invitations has declined, reflecting not just workload but also a perception that reviewing is uncompensated labor that carries no credit in academic promotion decisions.

The introduction of AI-generated manuscripts has added a further layer of pressure. Some journals have reported seeing a noticeable increase in submission volume since late 2022, which editors attribute at least partly to manuscripts that were drafted or assisted by large language models. More submissions mean more review requests sent to the same finite pool of researchers. Reviewer fatigue, often described anecdotally, shows up in declining acceptance rates and increasing rates of abandonment after acceptance.

For medical journals specifically, the reviewer shortage creates a particular problem. Clinical research manuscripts require reviewers with narrow specialty expertise. A methodologist who can evaluate a randomized trial with a complex adaptive design is not interchangeable with a cardiologist who can assess the clinical plausibility of endpoint selection. When editorial offices cast wide invitation nets to fill reviewer slots, the mismatch between reviewer expertise and manuscript content rises, which affects the quality of feedback authors receive.

The Biology Open Experiment: What Was Actually Done

Biology Open, published by The Company of Biologists, began piloting paid peer review in July 2024 with a small group of pre-contracted reviewers. The model differs from simply offering a cash bonus to anyone who agrees to review. Instead, the journal built a pool of contracted reviewers in advance, matched each submission to appropriate expertise within that pool, and paid reviewers upon completion of a report that met both a timing requirement and a quality threshold assessed by the handling editor. The payment of £220 per manuscript was not offered to the general reviewer community on a per-invitation basis but flowed through this contracted pool.

From April 2025, the Fast and Fair pathway became the default for all direct submissions to the journal, except in cases where the contracted pool lacked sufficient expertise for a given manuscript. In the same month, the journal phased out conventional voluntary peer review for new submissions entirely. The June 2026 preprint by editor-in-chief Daniel Gorelick and managing editor Alejandra Clark reported results covering manuscripts submitted through 2025 under the expanded model.

The last two rows in that table are the ones that matter most for interpreting the results. Acceptance rates and rejection rates remained broadly similar between the paid and conventional pathways. The editorial decisions themselves did not appear to change. The payment changed how quickly and reliably reviews were received, not what editors did with them. That is the interpretation the journal's editors offered, and it is an important caveat for anyone reading the headline numbers.

Earlier Experiments and What They Found

The Biology Open results are the largest and most thoroughly documented experiment to date, but they were not the first. In 2023, the journal Critical Care Medicine ran a six-month quasi-randomized study with 715 researchers who had been invited to review manuscripts. Half were offered $250 for completing a review, half received the standard acknowledgment. Among those offered payment, 53 percent accepted the invitation, compared with 48 percent in the unpaid group. The paid reviewers returned their reports about one day sooner on average, and quality assessments by editors found no meaningful difference between the two groups.

The Critical Care Medicine numbers are modest: a five-percentage-point increase in acceptance and a one-day improvement in turnaround. They do not look anything like the Biology Open results. The likely explanation is structural. Offering a discretionary bonus to whoever accepts a conventional invitation is not the same as building a pre-contracted reviewer pool that has already committed to the workload. The Biology Open model removes the invitation-and-wait step almost entirely. Reviewers in the pool have agreed in advance to respond quickly; payment reinforces that commitment rather than creating it from scratch.

A broader survey of journals that have tried monetary incentives, compiled in a 2026 Inside Higher Ed report, found that journals reporting faster publishing times were those that combined payment with structural changes to the review process rather than those that simply added a payment offer to an unchanged invitation workflow. That pattern suggests the payment works partly because it changes what reviewers are recruited into, not only because it provides a financial motive to review.

The Arguments Against Paying Reviewers

The case against paying reviewers is not simply that it costs money. The objections are substantive, and some are more durable than they first appear.

The most often cited concern is that payment will attract reviewers who are motivated by the money rather than by expertise and intellectual engagement. This is the commoditization argument: if reviewing becomes a gig, it will attract people who treat it like a gig. On this view, the quality advantage of voluntary review comes precisely from the fact that only sufficiently committed researchers bother to respond. Pre-contracted reviewer pools, as in the Biology Open model, address this partly, since the pool is assembled by the journal based on expertise rather than self-selection. But they do not address it entirely. As any paid reviewer pool scales, it becomes harder to maintain the matching quality that distinguishes it from a marketplace.

A second concern is cost, and for medical journals it is a realistic one. At $250 per review and two or three reviewers per manuscript, a mid-sized medical journal receiving several thousand submissions annually would need to find hundreds of thousands of dollars in annual reviewer compensation. The Biology Open model has the advantage of working within a nonprofit publisher with a specific mission, and it is not obvious that the financial structure transfers to a commercial medical journal or a society journal operating on a thin margin. Proposals have circulated to allow APCs to include a reviewer compensation line, or to cap APC eligibility at journals that use transparent, paid peer review, but these remain proposals rather than implemented policy.

There is also a conflict-of-interest question, particularly relevant in medical publishing. If a reviewer is paid by the journal for a positive review process, does that create an incentive toward less critical assessment? The Biology Open data does not support this worry for their model, since rejection rates remained similar across paid and conventional pathways. But medical research involves higher stakes than biology, and any payment arrangement in clinical research publishing would need to be designed and reported with transparency about how editorial independence is maintained.

Other Models Being Tested

Payment in cash is only one of several approaches journals have tried in response to the reviewer shortage. Some journals now offer reviewers credits that can offset article processing charges, which is a useful incentive for authors at institutions without APC coverage but less valuable to researchers whose APCs are fully funded. Others have moved toward formal certification programs that generate a record of review activity that can appear on CVs and grant applications, addressing the absence of academic credit for reviewing rather than the absence of financial compensation.

The journal eLife shifted to a model in 2023 in which peer review no longer results in accept-or-reject decisions; it results in a published review report that accompanies whatever version of the paper the authors decide to post. This is a structural change rather than an incentive change, but it has implications for reviewer motivation: if your review will be published, the bar for thoroughness shifts. Whether that shift improves or worsens the reviewer shortage depends on whether researchers find public recognition motivating or find the accountability of public review discouraging.

A proposal that has attracted serious discussion in 2026 would tie NIH APC cap policy to journal peer review practices. Under versions of this idea, journals that compensate reviewers and publish review reports openly would be eligible for higher APC caps under any NIH funding guidelines. This would create a financial incentive for journals, rather than for individual reviewers, to adopt transparent paid review models. Whether the proposal advances to policy depends on the outcome of a broader NIH grant-policy overhaul that is still working through a public comment period.

What This Means If You Are Submitting a Medical Manuscript

For authors in the middle of a submission decision right now, the Biology Open results have limited direct application. The journal is a biology title, not a clinical research journal. The fast-track pathway requires a manuscript to fit the contracted reviewer pool's expertise. And even if more medical journals adopt similar models, they will not all do so on the same timeline or with the same quality controls. That said, a few practical inferences are reasonable.

First, decision speed is becoming a visible dimension of journal selection in a way it was not five years ago. When a journal publishes data on its median time to first decision, that number is now comparable across journals in a way that impact factor and acceptance rate are not, because it is directly experienced. Authors who track submission timelines at the journals they target will increasingly find those numbers varying by two to four weeks depending on whether the journal has adopted faster review structures. If you are submitting a time-sensitive result, this matters.

Second, if you are invited to review for a journal that pays reviewers, the invitation deserves a different kind of consideration than a standard request. A paid review model typically involves a tighter turnaround commitment, often seven to ten days. If you accept, you are accepting both the payment and the deadline. Treating a paid review invitation the way many researchers treat conventional invitations, by accepting and then submitting the report three weeks late or not at all, defeats the model. Journals that track reviewer reliability in the context of paid pools may eventually use that history when deciding whether to include reviewers in future contracts.

Third, paid peer review models, if they spread, will probably be adopted first by journals that already have the infrastructure and funding to support them, which skews toward larger publishers and well-funded learned societies. Smaller specialty medical journals are less likely to move quickly. The reviewer shortage tends to be worse at high-volume journals, so large publishers have the strongest financial motivation to address it. Do not assume that a journal's adoption of faster review structures changes anything about its editorial standards or its fit for your research.

Transparency and What to Look For in Journal Policies

If you want to know whether a journal you are considering uses a paid or incentivized review model, the journal's peer review information page is the first place to look. Biology Open publishes its Fast and Fair model description, payment amounts, and eligibility conditions openly, which is good practice. Not all journals that have tried incentive programs have been equally transparent about the terms.

Journals that compensate reviewers through APC credits or professional development funding rather than cash may not describe this prominently. A journal that routes manuscript processing through a third-party editorial service may have review timing and compensation structures that are not fully disclosed in its author-facing materials. The peer review information page sometimes says more than the author guidelines page. If a journal publishes annual statistics on acceptance rates, decision timing, and reviewer participation, that is a positive indicator of transparency regardless of whether it pays reviewers.

For medical journals specifically, look for how the journal handles potential conflicts of interest in its peer review. Any journal using a contracted reviewer pool should publish information on how it manages conflicts of interest within that pool, how it handles manuscripts from authors who are themselves in the reviewer pool, and whether reviews are published or remain confidential. These are not concerns unique to paid review, but they are sharper in a paid model because the reviewer's relationship with the journal is more formal.

Where Medical Journals Are Likely to Go From Here

The Biology Open results are the most rigorous evidence that a structured paid review model can dramatically reduce decision times without destabilizing editorial quality. Whether medical journals follow depends on a mix of financial, cultural, and regulatory factors that vary considerably across the landscape.

The journals most likely to experiment with payment in the near term are mid-tier open access journals that compete on turnaround time and that have enough APC revenue to absorb reviewer costs. High-impact medical journals like the New England Journal of Medicine, The Lancet, JAMA, and the BMJ are unlikely to move quickly, partly because their reviewer prestige model is itself part of their brand. Invitations from flagship journals carry professional cache that cash payments at a lesser-known journal do not replace.

The more probable near-term development is a hybrid: some journals adopting fast-track paid pathways as an opt-in alternative to standard review, similar to how some journals now offer expedited editorial assessment for an additional fee. Authors who need a decision within 30 days might pay a premium that goes in part to fund accelerated reviewer compensation. This is not a reform of peer review so much as a two-tier system, and it carries its own equity concerns.

For now, the most useful thing a medical author can do is watch which journals start publishing transparent data on reviewer payment, timelines, and quality outcomes. The Biology Open approach is notable as much for its transparency about what it tried and what it found as for the results themselves. Journals willing to share that data deserve the attention of authors who care not just about where they publish, but about whether the review they receive is reliable.

Further Reading